News

GR-MD-02 targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. The trial, which has enrolled 30 patients with advanced fibrosis, will last for

The new macromolecule features various specialized components that create a triple-play action to avoid drug resistance. A specialized component of the macromolecule allows better hydrogen bonds with electrostatic

The commission granted approval for Bristol-Myers Squibb’s (BMS) Opdivo in combination with Yervoy to treat advanced (unresectable or metastatic) melanoma in adults. In the first Phase 3, double-blind,

To develop drugs that would prevent viruses from causing infections, researchers need to know the genetic mechanisms that viruses use to infect healthy cells. Those mechanisms become the

The study is entitled "A Double-Blind Placebo-Controlled Phase IIb Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults

JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars1 and monoclonal antibodies (mAbs) for late-stage clinical trials and commercial supply. The facility will

Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported

EGFR is an important molecular target for drug treatment; however, the lack of relevant experimental models bearing non-canonical EGFR mutations (such as exon 20 insertions) has been a

The regulator confirmed that the proposed comparator is acceptable and the trial design would meet the requirements established in its guidance for ABSSSI studies. In addition, the FDA